SUISENG Խորվաթիա - խորվաթերեն - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

suiseng

laboratorios hipra, s.a., avda. la selva, 135, 17170 amer (girona), Španjolska - fimbrijski adhezin f4ab e. coli ; fimbrijski adhezin f4ac e. coli ; fimbrijski adhezin f5 e. coli ; fimbrijski adhezin f6 e. coli ; enterotoksoid lt e. coli ; toksoid clostridium perfringens, tip c; toksoid clostridium novyi, tip b - suspenzija za injekciju - imunološki vmp - svinja (krmača i nazimica)

BoviBio ROTACOL Խորվաթիա - խորվաթերեն - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

bovibio rotacol

vet consulting d.o.o., matije gupca 42, 43500 daruvar, hrvatska - inaktivirani rotavirus goveda, soj tm-91;; inaktivirani koronavirus goveda, soj c-197; ; inaktivirana e. coli - 3 serovara iz enteropatogenih sojeva o8:k35, k99; o9:k35, k99; o101:k30, k99 - emulzija za injekciju - goveda (steonih junica i krava)

Purevax RCP FeLV Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh FeLV Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

purevax rcpch felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Arexvy Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusa - cjepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Purevax RC Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

purevax rc

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Purevax RCPCh Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Porcilis PCV ID Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

porcilis pcv id

intervet international b.v. - svinjski circovirus tip 2 orf2 podjedinica antigena - immunologicals for suidae, inactivated viral vaccines - svinje - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

Suiseng Diff/A Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svinje - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.